Novelgenix Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 0.18 M
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -95.89%
- Profit Growth 6.23%
- Ebitda 5.41%
- Net Worth -3080.52%
- Total Assets -28.96%
About Novelgenix Therapeutics
Novelgenix Therapeutics Private Limited (NTPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 June 2011 and has a history of 13 years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 0.18 M, as per Ministry of Corporate Affairs (MCA) records.
Shivprakash Chinnappa, Monika Verma, and Harsh Rathnam serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74140GJ2011PTC065969
-
Company No.
065969
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jun 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Novelgenix Therapeutics Private Limited offer?
Novelgenix Therapeutics Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Company Law & Labour Law Consultants, Statutory Compliance Services, Research and Development (R&D) Work, Product Development Research, Rapid Test Kit, Diagnostic Test Kit, Computer and Networking Solutions, Networking Solutions.
Who are the key members and board of directors at Novelgenix Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivprakash Chinnappa
|
Managing Director | 20-Jun-2011 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Monika Verma
|
Director | Current | |
|
Harsh Rathnam
|
Director | 09-Jun-2022 | Current |
Financial Performance of Novelgenix Therapeutics.
Novelgenix Therapeutics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.89% decrease. The company also saw a slight improvement in profitability, with a 6.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 3080.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novelgenix Therapeutics?
In 2023, Novelgenix Therapeutics had a promoter holding of 83.78% and a public holding of 16.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Intervein Laboratories Private LimitedShivprakash Chinnappa is a mutual person
-
Avance Phytotherapies Private LimitedShivprakash Chinnappa and Harsh Rathnam are mutual person
-
Synchron Research Services Private LimitedShivprakash Chinnappa is a mutual person
-
Apiqule Pharmachem LlpShivprakash Chinnappa and Harsh Rathnam are mutual person
-
Alinda Healthcare Private Limited
Monika Verma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novelgenix Therapeutics?
Unlock and access historical data on people associated with Novelgenix Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novelgenix Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novelgenix Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
